RP-HPLC METHOD FOR SIMULTATANEOUS DETERMINATION OF ATORVASTATIN CALCIUM, OLMESARTAN MEDOXOMIL, CANDESARTAN, HYDROCHLOROTHIAZIDE AND CHLORTHALIDONE – APPLICATION TO COMMERCIALLY AVAILABLE DRUG PRODUCTS
HTML Full TextRP-HPLC METHOD FOR SIMULTATANEOUS DETERMINATION OF ATORVASTATIN CALCIUM, OLMESARTAN MEDOXOMIL, CANDESARTAN, HYDROCHLOROTHIAZIDE AND CHLORTHALIDONE – APPLICATION TO COMMERCIALLY AVAILABLE DRUG PRODUCTS
R.A. Mhaske*1,S. Sahasrabudhe 1, A.A. Mhaske 1 and D. J. Garole 2
Shri Jagdishprasad Jhabarmal Tiberewala University 1, J.B. Nagar, Andheri (E), Mumbai– 400 059, Maharashtra, India
Department of Organic Chemistry, North Maharashtra University 2, Jalgaon, 425001, Maharashtra, India
ABSTRACT:A simple, precise and stability-indicating HPLC method was developed and validated for the simultaneous determination of anti-hypertensive drugs Atorvastatin Calcium, Olmesartan Medoxomil, Candesartan, diuretics Hydrochlorothiazide and Chlorthalidone. The separation was achieved on Cosmosil PAQ (Length 150 mm × Diameter 4.6 mm Particle size 5 μm) column with gradient flow. The mobile phase at a flow rate of 1.0 mL min−1 consisted of 0.05 M sodium dihydrogen phosphate buffer and acetonitrile (Gradient ratio). The UV detection was carried out at 220 nm. The method was successfully validated in accordance to ICH guidelines. Further, the validated method was applied for commercially available pharmaceutical dosage form.
| Keywords:RP-HPLC,
Anti-hypertensive, Diuretic drugs, Validation |
INTRODUCTION:The parent guideline on drug stability testing Q1A (R2) issued by International Conference on Harmonization (ICH) stipulates stress studies to be carried out on a drug in order to establish the drug's inherent stability characteristics 1-2. Literature studies show various analytical methods reported for the estimation of individual, binary or tertiary combination of anti-hypertensive drugs or in combination with diuretics 3-12. Recently, HPLC method with fluorescence detection for simultaneous determination of chlorthalidone, valsartan and fluvastatin from human plasma has been reported 13.
The HPLC-MS/MS method for simultaneous estimation of atenolol, bisoprolol, hydrochlorothiazide, chlorthalidone, salicylic acid, enalapril and its active metabolite enalaprilat, valsartan and fluvastatin is also reported 14.
However, so far, no method was reported for the simultaneous determination in combination for Atorvastatin Calcium, Olmesartan Medoxomil, Candesartan, Hydrochlorothiazide, Chlorthalidone and its application to pharmaceutical samples.
An attempt was made in this study to develop a rapid, economical, precise and accurate stability-indicating assay method for simultaneous estimation of Atorvastatin Calcium, Olmesartan Medoxomil, Candesartan, Hydrochlorothiazide and Chlorthalidone in tablet formulation.
The proposed method is rapid, simple, accurate, and reproducible, and can be successfully employed in the routine analysis of both these drugs simultaneously, in tablet dosage form.
MATERIAL AND METHODS:
- Chemicals and reagents: Drug substances were provided by Sharon Biomedicine, India. All the chemicals and reagents sodium hydroxide, hydrochloric acid, monobasic sodium dihydrogen phosphate, hydrogen peroxide (30 %) was used of Analytical grade while, Acetonitrile was procured from Merck (Germany). A Millipore Milli Q plus water purification system (Milford, USA), was used to prepare distilled water (>18 μΩ). The commercially available drug products were used as OLSAR 20 (Omlesartan - 20 mg, Unichem Laboratories, India), OLMAX H (Olmesartan Medoxomil - 20 mg and Hydrochlorothiazide - 12.5 mg; Glenmark, India), Atocor-5 (Atorvastatin Calcium 5 mg, Dr. Reddys, India).
- Instruments: Integrated HPLC system, Ultimate 3000 manufactured by Dionex (Germany) was used for method development and method validation. This system comprised of a quaternary gradient pump, auto sampler, column oven and a photodiode array detector. PC installed Chromeleon software was used to record and integrates the chromatograms. The analysis was carried out at ambient temperature. Photostability studies were performed in a photostability chamber, from Thermolab (India).
- Chromatographic conditions: Cosmosil PAQ (Length 150 mm × Diameter 4.6 mm Particle size 5 μm) analytical column from Nacalai Tesque INC, Japan was used as a stationary phase. The flow rate was 1.0 mL min−1 and the detector was set at 220 nm. The volume of the sample solution injected was 10 μL. The gradient mobile phase consisted of 0.05 M sodium dihydrogen phosphate buffer and acetonitrile (Mobile Phase-B) with the gradient as mentioned in Table 1. A membrane filter of 0.45 μm porosity was used to filter and degas the mobile phase.
- Standard and Test solutions: Weighed accurately about 50 mg of each Atorvastatin Calcium, Olmesartan Medoxomil, Candesartan, Hydrochlorothiazide and Chlorthalidone reference standard into 50 ml volumetric flask. Added to it 20.0 ml methanol and sonicated to dissolve. Diluted this solution up to volume with diluent (Buffer: Methanol 30:70 v/v). Pipette out 5.0 ml of this solution into 50 ml volumetric flask and diluted to volume with diluent. (100 μg mL−1 each of Atorvastatin Calcium, Olmesartan Medoxomil, Candesartan, Hydrochlorothiazide and Chlorthalidone). Similarly, the test solutions were prepared at same concentration using same diluents. (100 μg mL−1 of each).
TABLE 1: MOBILE PHASE GRADIENT FOR CHROMATOGRAPHIC METHOD
| Time (min) | % 0.05 M sodium dihydrogenphosphate buffer | % Acetonitrile |
| 0 | 70 | 30 |
| 3 | 70 | 30 |
| 8 | 40 | 60 |
| 11 | 20 | 80 |
| 15 | 20 | 80 |
| 18 | 70 | 30 |
Method Development: A variety of mobile phases were investigated in the development of a stability-indicating LC method for the analysis of Atorvastatin Calcium, Olmesartan Medoxomil, Candesartan, Hydrochlorothiazide and Chlorthalidone drug substances. The suitability of mobile phase was decided on the basis of selectivity and sensitivity of the assay, stability studies and separation among impurities formed during forced degradation studies.
- Wavelength Selection: The individual drug substance solution at concentration of 100μg mL−1 in diluent was scanned on PDA from 190 nm to 400 nm. The maximum wavelength were observed Hydrochlorothiazide (224 nm and 271 nm), Chlorthalidone (196 nm), Olmesartan Medoxomil (196 nm and 258 nm), Atorvastatin Calcium (194 nm and 246 nm), Candesartan (197 nm, 253 nm and 305 nm). However detection was carried out at 220 nm on basis of higher response (Fig. 1 and Table 2).
FIG. 1: UV SPECTRUM FOR DRUG SUBSTANCES IN DILUENTS
TABLE 2: AREA RESPONSE OF PEAKS AT DIFFERENT WAVELENGTHS
| Wavelength (nm) | HTZ | CL | OS | AC | CS |
| 220 | 99.732 | 76.133 | 31.913 | 31.504 | 72.216 |
| 230 | 60.948 | 54.561 | 25.560 | 30.871 | 48.029 |
| 240 | 7.573 | 29.388 | 23.006 | 34.822 | 28.576 |
| 250 | 9.9846 | 11.406 | 25.315 | 35.286 | 26.230 |
| 260 | 32.419 | 6.753 | 26.583 | 30.895 | 25.263 |
| 280 | 36.045 | 4.314 | 9.704 | 22.405 | 13.446 |
| 300 | 7.720 | 0.130 | 0.372 | 8.941 | 8.546 |
Method Validation: The optimized chromatographic conditions were validated by evaluating specificity-Forced degradation, linearity, precision, accuracy, robustness and system suitability parameters in accordance with the ICH guideline Q2 (R1) 2.
Specificity- Forced Degradation Study:
- Acid Hydrolysis: Forced degradation study was conducted on 5 ml stock solution of standard solution containing 1000 μg mL−1 of each drug substances by exposing with 5ml of 1N hydrochloric acid for 3 hours at room temperature. Then neutralized with base (when necessary) and dilute up to 50 ml with diluent.
- Base Hydrolysis: Forced degradation study was conducted on 5 ml stock solution of standard solution containing 1000 μg mL−1 of each drug substances by exposing with 5ml of 0.1N sodium hydroxide for 30 minutes at room temperature. Then neutralized with acid and dilute up to 50 ml with diluent.
- Oxidation: Forced degradation study was conducted on 5 ml stock solution of standard solution containing 1000 μg mL−1 of each drug substances by exposing with 5ml of 5% H2O2 for 30 minutes at room temperature. Then dilute up to 50 ml with diluent.
- Thermal degradation: Solid drugs powder was kept in dry oven at 105°C for 24 hours.
- Photolysis: Photolysis studies were carried out on solid drugs, their combination and their dosage form. The sample in a petri plate was spread as a thin layer (1 mm) and exposed to light in a photostability chamber. The method's analytical data were collected at a single wavelength of 220 nm. Additional PDA detector data were collected for the peak purity evaluation. The chromatograms were extracted for Peak purity and demonstrated as in Fig. 2a, b, c, d, e, f, g and Table 3.
a) Blank solution
b) Standards solution
c) Specificity-Acid hydrolysis
d) Specificity-Alkaline hydrolysis
e) Specificity-Peroxide oxidation
f) Specificity Photolytic degradation
g) Specificity-Thermal degradation
FIG. 2: CHROMATOGRAMS FOR STRESSED CONDITIONS
TABLE 3: RESULTS FOR FORCED DEGRADATION STUDY
| Degradation Condition | HTZ | CL | OS | AC | CS | |
| Acid hydrolysis | % Degradation | 0.7 | 60.0 | 63.9 | 44.8 | 20.1 |
| Peak purity | 1000 | 1000 | 1000 | 1000 | 1000 | |
| Alkaline hydrolysis | % Degradation | 0.7 | 0.8 | 73.2 | 2.2 | 2.3 |
| Peak purity | 1000 | 1000 | 1000 | 1000 | 1000 | |
| Peroxide Oxidation | % Degradation | 4.8 | 1.6 | 14.9 | 2.4 | 1.1 |
| Peak purity | 999 | 1000 | 1000 | 998 | 1000 | |
| Photolytic degradation | % Degradation | 0.7 | 1.36 | 0.0 | 0.2 | 0.2 |
| Peak purity | 1000 | 1000 | 1000 | 998 | 1000 | |
| Thermal degradation | % Degradation | 1.2 | 0.0 | 0.0 | 0.0 | 0.0 |
| Peak purity | 1000 | 1000 | 1000 | 998 | 1000 |
Linearity: Standard stock solution of the drug was diluted to prepare linearity standard solutions in the concentration range of 10 –150 μg mL−1 for all Hydrochlorothiazide, Chlorthalidone, Olmesartan Medoxomil, Atorvastatin Calcium, and Candesartan. Three sets of such solutions were prepared. Each set was analyzed to plot a calibration curve. Slope, intercept and coefficient of determination (r2) of the calibration curves were calculated to ascertain linearity of the method (Fig. 3 and Table 4).
FIG. 3: LINEARITY CURVE WITH CORRELATION CO-EFFICIENT
Recovery: Recovery of the method was determined by analyzed the drug products and synthetic mixture of drug products with 50%, 100% and 150% levels. These mixtures were analyzed by the proposed method. The experiment was performed in triplicate and recovery (%); RSD (%) were calculated (Table 5 and 6).
Precision: The precision of the proposed method was evaluated by carrying out six independent assays of test samples. RSD (%) of six assay values obtained was calculated. Intermediate precision was carried out by analyzing the samples by a different analyst on another instrument (Table 7).
Robustness: The robustness was studied by evaluating the effect of small but deliberate variations in the chromatographic conditions. The conditions studied were wavelength (altered by ±0.3 nm), column oven temperature (altered by ±5 ° C) and pH of buffer in mobile phase (altered by ± 0.2). These chromatographic variations were evaluated for resolution between all drug substances (Table 8 to 10).
Solution stability: To assess the solution stability, standard and test solutions were kept at 25 °C (laboratory temperature) for 24 hrs (Table 11).
System Suitability: The system suitability parameters with respect to theoretical plates, tailing factor, repeatability and resolution between peaks of all drug substances were defined (Table 12).
TABLE 4: SLOPE, INTERCEPT AND REGRESSION COEFFICIENT
| Drug substance | Slope | Intercept | Regression(r2) |
| Hydrochlorothiazide (HTZ) | 1.016 | 0.548 | 1.000 |
| Chlorthalidone (CL) | 0.755 | -0.225 | 1.000 |
| Olmesartan Medoxomil (OS) | 0.444 | 1.179 | 1.000 |
| Atorvastatin Calcium (AC) | 0.928 | -1.202 | 1.000 |
| Candesartan (CS) | 2.370 | 0.053 | 1.000 |
TABLE 5: RECOVERY FROM COMMERCIALLY AVAILABLE SAMPLES
| % Recovery | OLSAR 20 TabletsOS 20mg (Unichem Lab Ltd) | OLMAX H TabletsOS 20mg and HTZ 12.5mg (Glenmark Pharma Ltd) | Atocor TabletsAC 5mg (Dr. Reddys Ltd) | |
| Recovery (%) For OS | Recovery (%) For OS | Recovery (%) For HTZ | Recovery (%) For AC | |
| 50 % | 99.45100.13
98.65 |
98.5699.49
98.70 |
102.3798.98
101.13 |
101.08100.72
99.30 |
| 100 % | 102.00101.50
101.93 |
98.24100.02
98.40 |
101.10101.88
101.21 |
98.70101.61
100.90 |
| 150 % | 101.0898.85
101.76 |
98.9199.53
100.87 |
99.58100.19
100.80 |
101.6899.86
101.91 |
| Avg | 100.60 | 99.02 | 100.86 | 100.64 |
| RSD | 1.34 | 0.87 | 1.06 | 1.11 |
TABLE 6: RECOVERY ON SYNTHETIC MIXTURE OF ALL FIVE DRUG SUBSTANCE
| % Recovery | % Assay | ||||
| HTZ | CL | OS | AC | CS | |
| Level – 50% | 101.2798.20
99.83 |
100.1498.57
99.68 |
100.72102.34
99.96 |
100.5999.83
102.18 |
99.7597.32
99.41 |
| Level – 100% | 102.6499.82
100.69 |
102.8097.87
100.32 |
101.68100.46
101.00 |
100.0499.72
101.07 |
101.84100.43
98.22 |
| Level – 150% | 99.9697.52
99.25 |
100.8897.76
100.80 |
100.71100.44
99.63 |
100.2898.83
100.80 |
101.0899.64
97.99 |
| Average | 99.91 | 99.87 | 100.77 | 100.37 | 99.52 |
| RSD | 1.55 | 1.60 | 0.83 | 0.94 | 1.51 |
*Chlorthalidone and Candesartan drug substances spiked with Olmax H and Atocor drug products.
TABLE 7: PRECESSION
| % Assay - Repeatability | % Assay - Intermediate Precision | |||||||||
| Sr. Nos. | HTZ | CL | OS | AC | CS | HTZ | CL | OS | AC | CS |
| 1 | 98.04 | 100.74 | 101.19 | 100.46 | 99.99 | 101.76 | 98.20 | 99.78 | 98.31 | 99.13 |
| 2 | 99.82 | 101.89 | 99.50 | 100.21 | 100.20 | 99.72 | 100.11 | 99.73 | 101.20 | 99.80 |
| 6 | 100.02 | 100.15 | 99.65 | 100.171 | 100.14 | 99.70 | 100.02 | 99.83 | 99.88 | 100.01 |
| 4 | 98.57 | 99.60 | 98.66 | 99.94 | 98.35 | 99.98 | 100.17 | 101.65 | 101.92 | 101.08 |
| 5 | 100.11 | 100.33 | 99.73 | 98.51 | 101.96 | 100.04 | 99.95 | 98.42 | 99.89 | 98.47 |
| 6 | 99.97 | 100.38 | 101.77 | 99.10 | 100.13 | 101.04 | 99.94 | 98.46 | 100.35 | 99.84 |
| Avg | 99.42 | 100.52 | 100.08 | 99.73 | 100.13 | 100.39 | 99.73 | 99.65 | 100.26 | 99.72 |
| RSD | 0.89 | 0.77 | 1.16 | 0.76 | 1.14 | 0.82 | 0.76 | 1.19 | 1.24 | 0.88 |
| Average for Precision and Intermediate precision | 99.79 | 100.14 | 99.99 | 99.96 | 99.93 | |||||
| RSD for Precision and Intermediate precision | 0.96 | 0.83 | 1.14 | 1.02 | 1.00 | |||||
TABLE 8: CHANGE IN WAVELENGTH
| Wavelength | % Assay | ||||
| HTZ | CL | OS | AC | CS | |
| 217 nm | 99.79 | 99.91 | 99.69 | 99.95 | 99.77 |
| 220 nm | 99.93 | 100.03 | 99.80 | 100.33 | 100.25 |
| 223 nm | 99.59 | 99.92 | 99.71 | 100.06 | 99.84 |
| Average | 99.77 | 99.95 | 99.73 | 100.11 | 99.95 |
| RSD | 0.17 | 0.07 | 0.06 | 0.20 | 0.26 |
TABLE 9: CHANGE IN COLUMN OVEN TEMPERATURE
| Column oven temperature | % Assay | ||||
| HTZ | CL | OS | AC | CS | |
| 20°C | 99.98 | 100.14 | 99.76 | 100.16 | 100.08 |
| 25°C | 99.93 | 100.03 | 99.80 | 100.33 | 100.25 |
| 30°C | 99.89 | 100.07 | 99.74 | 100.35 | 100.29 |
| Average | 99.93 | 100.08 | 99.77 | 100.28 | 100.21 |
| RSD | 0.05 | 0.06 | 0.03 | 0.10 | 0.11 |
TABLE 10: CHANGE IN pH OF BUFFER SOLUTION IN MOBILE PHASE
| pH of buffer | % Assay% Assay of | ||||
| HTZ | CL | OS | AC | CS | |
| pH 4.0 | 99.93 | 100.32 | 99.77 | 100.30 | 100.32 |
| pH 4.2 | 99.93 | 100.03 | 99.80 | 100.33 | 100.25 |
| pH 4.4 | 99.90 | 100.17 | 99.79 | 100.17 | 100.06 |
| Average | 99.92 | 100.17 | 99.79 | 100.27 | 100.21 |
| RSD | 0.02 | 0.14 | 0.02 | 0.08 | 0.13 |
TABLE 11: RESULTS FOR SOLUTION STABILITY
| Time (Hours) | % Assay | ||||
| HTZ | CL | OS | AC | CS | |
| Initial | 99.87 | 100.13 | 99.79 | 99.97 | 100.06 |
| 3 | 99.88 | 100.52 | 99.30 | 99.58 | 100.11 |
| 6 | 99.73 | 99.97 | 79.29 | 99.25 | 100.57 |
| 12 | 96.90 | 98.77 | 62.90 | 97.38 | 100.62 |
| 18 | 96.46 | 97.04 | 55.31 | 95.19 | 100.84 |
| 24 | 96.08 | 95.66 | 53.75 | 94.75 | 96.56 |
TABLE 12: CHROMATOGRAPHIC PARAMETERS OF SYSTEM SUITABILITY
| Drug substances | RT (min) | Theoretical plates | Symmetry | Resolution | Peak purity |
| HTZ | 3.42 | 6612 | 1.42 | - | 1000 |
| CL | 4.65 | 7428 | 1.34 | 6.34 | 1000 |
| OS | 9.42 | 71558 | 1.20 | 26.82 | 999 |
| AC | 10.90 | 101530 | 1.24 | 10.67 | 999 |
| CS | 13.04 | 132362 | 1.22 | 15.26 | 1000 |
RESULTS AND DISCUSSION:
HPLC Method Development: The maximum absorption wavelength of the reference drug solution and of the forcefully degraded drug solution was found to be 220 nm. This was observed from the UV absorption spectra (Fig. 1) and was selected as detection wavelength for LC analysis. The main objective of this chromatographic method was separation of degraded impurities from all drugs.
Forced degradation study revealed a critical separation of closely eluting impurity formed from the Hydrochlorothiazide, Chlorthalidone, Olmesartan Medoxomil, Atorvastatin Calcium and Candesartan peaks. PAQ (Length 150 mm × Diameter 4.6 mm, Particle size 5 μm) helped in resolving all peaks as the column had carbon loading approx 11% against conventional ODS. This effect was observed by using the mobile phase 0.05 sodium hydrogen phosphate (pH 4.2) and acetonitrile in the gradient ratio.
Summary of Validation Parameters: The assay test method is validated for Specificity, Linearity, Precision, Accuracy (Recovery), Stability of Analytical Solution and Robustness and was found to be meeting the predetermined acceptance criteria.
The validated method is Specific, Linear, Precise, Accurate and Robust for determination of assay of Atorvastatin Calcium, Olmesartan Medoxomil, Candesartan, diuretics Hydrochlorothiazide and Chlorthalidone drug substances and drug products.
Hence, this method can be introduced into routine and stability analysis for the assay of Atorvastatin Calcium, Olmesartan Medoxomil, Candesartan, diuretics Hydrochlorothiazide and Chlorthalidone drug substances.
CONCLUSION: The stability indicating RP-HPLC assay method was developed and validated for simultaneous determination of Atorvastatin Calcium, Olmesartan Medoxomil, Candesartan, diuretics Hydrochlorothiazide and Chlorthalidone drug substances and drug products. The method was found to be simple, specific, Precise and Robust and can be applied for the routine and stability analysis for commercially available formulation.
ACKNOWLEDGEMENTS: The authors are thankful to entire team of JJT University and Mr. K Kaul, Mr. Lalit Mishra- Sharon Bio Medicine for their encouragement and support during the work.
REFERENCES:
- ICH, International Conference on Harmonization of Technical Requirements for Registration of Pharmaceuticals for Human Use, Stability Testing of New Drug Substances and Products Q1A (R2), 2003.
- ICH, International Conference on Harmonization of Technical Requirements for Registration of Pharmaceuticals for Human Use, Validation of analytical procedure: Text and Methodology Q2 (R1), 2005.
- Ashok K, Sathya A, Senthil K, Patil S, Prathap N B, Lokesh SB, Gopa V: Simultaneous Estimation of Olmesartan Medoxomil and Hydrochlorothiazide by RP-HPLC Method from Combined Dosage Form. Int J Res Pharm Sci 2010; 1(1): 24-27.
- Joshi SJ, Pradnya A. Karbhari S I, Bhoir KS, Bindu D Chhanda D: RP-HPLC method for simultaneous estimation of bisoprolol fumarate and hydrochlorothiazide in tablet formulation. Journal of Pharmaceutical and Biomedical Analysis 2010; 52(3): 362-371
- Pournima Patil, Vaishali Barge, Harinath More, Sachin Piswikar: Spectrophotometric method for simultaneously determination of Olmesartan Medoxomil and Amlodipine Besylate from tablet dosage form. International Journal of Current Pharmaceutical Research, volume 3, issue 2, 2011.
- Ashok K, Sathya A, kumar KS, Patil S and Chhanda D: RP-HPLC method for simultaneous estimation of bisoprolol fumarate and hydrochlorothiazide in tablet formulation. Journal of Pharmaceutical and Biomedical Analysis, 2010; 52 (3): 362-371.
- Feng G, Mengliang Z, Xiangyong C, Zhonghua W, Yantong S and Jingkai G: Simultaneous quantitation of hydrochlorothiazide and metoprolol in human plasma by liquid chromatography–tandem mass spectrometry. Journal of Pharmaceutical and Biomedical Analysis 2010; 52(1): 149-154.
- Thamake SL, Jadhav SD, Pishwikar SA: Development and validation of simultaneous estimation of Atorvastatin Calcium and Ramipril from Capsule dosage form by first order derivative spectroscopy. Asian J. Research Chem. 2(I) Jan-Mar2009, ISSN 0974-4269.
- Raveendra Babu Ganduri, Ramprasad A. Lanka, Srinivasu Pamidi, Jayachandra R. Peddareddigari, Mustafa Mohammed: New RP-HPLC Method for the determination of Olmesartan Medoxomil in Tablets dosage form. Eurasian Journal Analytical Chemistry, Vol 5, No 2 (2010)
- Alaa E. M. Khedr. Simultaneous Determination of Candesartan Cilexetil and Hydrochlorothiazide by High-Performance Liquid Chromatography. The Journal King Abdulaziz University - Medical Sciences, Vol 15, No 2 (2008)
- Wankhede SB, Tajne MR, Gupta KR and Wadodka SGRP-HPLC method for simultaneous estimation of telmisartan and hydrochlorothiazide in tablet dosage form. Indian Journal of Pharmaceutical Science Research 2007;69(2):298-300.
- Patel Jignesh, Dave J B, Patel C N and Patel Dhrumil. Q-Analysis Spectrophotometric methods for estimation of Candesartan Cilexetil and Hydrochlorothiazide in tablet dosage form. Journal of Chemical and Pharmaceutical, Research, ISSN No: 0975-7384 CODEN (USA): JCPRC5
- Oskar Gonzalez et al: Optimization and validation of a SPE-HPLC-PDA-fluorescence method for the simultaneous determination of drugs used in combined cardiovascular therapy in human plasma. Journal of Pharmaceutical and Biomedical Analysis 2009; 50(4): 630-639.
- Gonzalez O, Iriarte G, Rico E, Ferreirós N, Maguregui MI, Alonso RM and Jiménez: RM.LC-MS/MS method for the determination of several drugs used in combined cardiovascular therapy in human plasma. J Chromatogr B Analyt Technol Biomed Life Sci 2010; 15(28): 2685-92.
Article Information
18
793-801
966KB
2041
English
IJPSR
R.A. Mhaske*, S. Sahasrabudhe , A.A. Mhaske and D. J. Garole
Asst General Manger – AMD, Sharon Bio Medicine, Plot L6, MIDC, Taloja- 410208, Taluka – Panvel, Dist Raigad, Maharashtra, India
25 October, 2011
29 November, 2011
21 February, 2012
http://dx.doi.org/10.13040/IJPSR.0975-8232.3(3).793-01
1-March-2012
Download